The McLean, Virginia-based firm closed a $3m deal to supply software and services to the London-based European Medicines Agency (EMEA) which provides reporting and analysis of drug safety for the European Union.
MicroStrategy says its technology was selected as the enterprise business intelligence standard for a community of 40,000 users made up of pharmaceutical companies, regulators, and healthcare professionals.
EMEA, which is a decentralized organization that promotes public and animal health, is coordinating the evaluation and supervision of medicinal products across the 25 European Union states.
MicroStrategy’s software will be used to analyze and report on clinical data stored in a large Oracle data warehouse.
Surprisingly, MicroStrategy officials in the US were yesterday unable to confirm the specific version of software involved in the deal or who the company beat off in the competitive tender.
MicroStrategy recently unveiled a new generation of its core business intelligence suite – called MicroStrategy 8 – which packs in a host of new tools and functionality aimed at non-technical users.
